COVID-19 Disease Severity Risk Factors for Pediatric Patients in Italy

  • Stefania Bellino
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Ornella Punzo
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Maria Cristina Rota
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Martina Del Manso
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Alberto Mateo Urdiales
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Xanthi Andrianou
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Massimo Fabiani
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Stefano Boros
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Flavia Riccardo
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Antonino Bella
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Antonietta Filia
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;
  • Giovanni Rezza
    General Directorate for Prevention, Ministry of Health, Rome, Italy; and
  • Alberto Villani
    General Pediatrics and Infectious Diseases Unit, Pediatric Hospital Bambino Gesù, Rome, Italy
  • Patrizio Pezzotti
    Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy;

説明

<jats:sec> <jats:title>OBJECTIVES:</jats:title> <jats:p>To describe the epidemiological and clinical characteristics of coronavirus disease (COVID-19) pediatric patients aged &lt;18 years in Italy.</jats:p> </jats:sec> <jats:sec> <jats:title>METHODS:</jats:title> <jats:p>Data from the national case-based surveillance system of confirmed COVID-19 infections until May 8, 2020, were analyzed. Demographic and clinical characteristics of subjects were summarized by age groups (0–1, 2–6, 7–12, 13–18 years), and risk factors for disease severity were evaluated by using a multilevel (clustered by region) multivariable logistic regression model. Furthermore, a comparison among children, adults, and elderly was performed.</jats:p> </jats:sec> <jats:sec> <jats:title>RESULTS:</jats:title> <jats:p>Pediatric patients (3836) accounted for 1.8% of total infections (216 305); the median age was 11 years, 51.4% were male, 13.3% were hospitalized, and 5.4% presented underlying medical conditions. The disease was mild in 32.4% of cases and severe in 4.3%, particularly in children ≤6 years old (10.8%); among 511 hospitalized patients, 3.5% were admitted in ICU, and 4 deaths occurred. Lower risk of disease severity was associated with increasing age and calendar time, whereas a higher risk was associated with preexisting underlying medical conditions (odds ratio = 2.80, 95% confidence interval = 1.74–4.48). Hospitalization rate, admission in ICU, disease severity, and days from symptoms onset to recovery significantly increased with age among children, adults and elderly.</jats:p> </jats:sec> <jats:sec> <jats:title>CONCLUSIONS:</jats:title> <jats:p>Data suggest that pediatric cases of COVID-19 are less severe than adults; however, age ≤1 year and the presence of underlying conditions represent severity risk factors. A better understanding of the infection in children may give important insights into disease pathogenesis, health care practices, and public health policies.</jats:p> </jats:sec>

収録刊行物

  • Pediatrics

    Pediatrics 146 (4), 2020-10-01

    American Academy of Pediatrics (AAP)

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ